Itacitinib Active Not Recruiting Phase 2 Trials for Non-Small Cell Lung Carcinoma (NSCLC) Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03425006Pembrolizumab and Itacitinib (INCB039110) for NSCLC